[Transcatheter renal arterial embolization in malignant renal neoplasms: clinical results and indications for use of the method in multi-profile hospitals].
The authors analyse the long-term and in-hospital results of treatment 29 patients with renal neoplasms, who underwent transcatheter renal arterial embolization and also discuss the benefits of transcatheter renal arterial embolization in other clinical situations. Transcatheter renal arterial embolization was performed with embosil for 23 patients (79.3%) and with concentrated alcohol for 6 patients (20.7%) before nephrectomy of advance renal tumour in 21 patients. Transcatheter renal arterial embolization was performed as palliative treatment in 8 patients. Complete embolization was achieved in 27 patients (93.1%), incomplete--in 2 patients (6.9%). Nephrectomy was performed after 22.14 +/- 9.28 days. The most evident post procedural reactions were moderately elevated temperature in 22 patients (75.9%), highly elevated temperature (> 38 degrees) in 7 patients (24.1%) and pain. Only 6 patients (20.7%) didn't feel pain. One hematoma was noticed in puncture region. After 5 years, 4 patients of 10 analysed patients are still alive (all-pT3, size of tumor 6.5-9 cm.). Two patients were not operated due to very big tumor and technical inoperability. Remaining 4 patients died during 2-3 years. As exclusion was one patient with inoperable renal tumor and lung metastases. After transcatheter renal arterial embolization he was alive 4 years. In conclusion, transcatheter renal arterial embolization was effective in diminishing the technical difficulties to remove advance tumors and in treatment of inoperable patients. It's rational to supply transcatheter renal arterial embolization with embolization and chemoembolization of primary and metastatic lesions.
Vaicekavicius
Edvardas
E
Kauno medicinos universiteto Kardiologijos institutas, Sukileliu 17, 3007 Kaunas. evaicek@takas.lt, invlab@kmu.lt
Pranculis
Andrius
A
D000368:Aged; D016461:Chemoembolization, Therapeutic; D004621:Embolization, Therapeutic; D000431:Ethanol / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009392:Nephrectomy; D010166:Palliative Care; D012077:Renal Artery; D017655:Silicon Compounds / Q000008:administration & dosage; D013997:Time Factors
D017655:Silicon Compounds; C091269:embosil; D000431:Ethanol